Cargando…

Experience of intravitreal triamcinolone acetonide for treatment of diabetic macular edema among Omani population

PURPOSE: The purpose of this study was to evaluate the outcome of intravitreal (IVT) triamcinolone in diabetic macular edema (DME). MATERIALS AND METHODS: A retrospective study of 42 eyes diagnosed clinically and supported with optical coherence tomography (OCT), with DME of more than 300 μm in thic...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Hinai, Ahmed, Wali, Upender Krishen, Rasool, Tayseer Abdul, Rizvi, Syed G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657160/
https://www.ncbi.nlm.nih.gov/pubmed/29118493
http://dx.doi.org/10.4103/ojo.OJO_173_2016
_version_ 1783273832024375296
author Al Hinai, Ahmed
Wali, Upender Krishen
Rasool, Tayseer Abdul
Rizvi, Syed G
author_facet Al Hinai, Ahmed
Wali, Upender Krishen
Rasool, Tayseer Abdul
Rizvi, Syed G
author_sort Al Hinai, Ahmed
collection PubMed
description PURPOSE: The purpose of this study was to evaluate the outcome of intravitreal (IVT) triamcinolone in diabetic macular edema (DME). MATERIALS AND METHODS: A retrospective study of 42 eyes diagnosed clinically and supported with optical coherence tomography (OCT), with DME of more than 300 μm in thickness. All eyes were injected with a single IVT injection of preservative free triamcinolone acetonide (TA) with dose of 4 mg. Patients were subjected to visual acuity (VA) and OCT on each follow-up visit which was continued for 6 months. The total number of IVT injections given was 48. Six eyes had a repeat injection. None of the eyes had any other IVT injection within 6 weeks of TA. Twenty-one eyes were pseudophakic. RESULTS: Mean age of the patients was 58.8 years. The mean central subfield thickness (CST) at baseline was 504.6 μm. At 6 weeks, the mean CST dropped by 183.6 μm (P < 0.00001). At 6-month follow-up, the mean CST had increased by 74.6 μm from 6 weeks level; however, the 6-month mean CST was 109 μ less than mean baseline thickness (P < 0.0005). The mean baseline VA was 0.80 LogMAR units. At 6 weeks, the mean VA dropped by 0.01 LogMAR. At 6 months, VA improved by 0.02 LogMAR units from baseline. Overall, VA improved in 47% eyes, dropped from baseline in 35% eyes, and remained unchanged in 18% eyes. CONCLUSION: Triamcinolone acetonide is a safe, effective, and promising therapy in DME.
format Online
Article
Text
id pubmed-5657160
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-56571602017-11-08 Experience of intravitreal triamcinolone acetonide for treatment of diabetic macular edema among Omani population Al Hinai, Ahmed Wali, Upender Krishen Rasool, Tayseer Abdul Rizvi, Syed G Oman J Ophthalmol Original Article PURPOSE: The purpose of this study was to evaluate the outcome of intravitreal (IVT) triamcinolone in diabetic macular edema (DME). MATERIALS AND METHODS: A retrospective study of 42 eyes diagnosed clinically and supported with optical coherence tomography (OCT), with DME of more than 300 μm in thickness. All eyes were injected with a single IVT injection of preservative free triamcinolone acetonide (TA) with dose of 4 mg. Patients were subjected to visual acuity (VA) and OCT on each follow-up visit which was continued for 6 months. The total number of IVT injections given was 48. Six eyes had a repeat injection. None of the eyes had any other IVT injection within 6 weeks of TA. Twenty-one eyes were pseudophakic. RESULTS: Mean age of the patients was 58.8 years. The mean central subfield thickness (CST) at baseline was 504.6 μm. At 6 weeks, the mean CST dropped by 183.6 μm (P < 0.00001). At 6-month follow-up, the mean CST had increased by 74.6 μm from 6 weeks level; however, the 6-month mean CST was 109 μ less than mean baseline thickness (P < 0.0005). The mean baseline VA was 0.80 LogMAR units. At 6 weeks, the mean VA dropped by 0.01 LogMAR. At 6 months, VA improved by 0.02 LogMAR units from baseline. Overall, VA improved in 47% eyes, dropped from baseline in 35% eyes, and remained unchanged in 18% eyes. CONCLUSION: Triamcinolone acetonide is a safe, effective, and promising therapy in DME. Medknow Publications & Media Pvt Ltd 2017 /pmc/articles/PMC5657160/ /pubmed/29118493 http://dx.doi.org/10.4103/ojo.OJO_173_2016 Text en Copyright: © 2017 Oman Ophthalmic Society http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Al Hinai, Ahmed
Wali, Upender Krishen
Rasool, Tayseer Abdul
Rizvi, Syed G
Experience of intravitreal triamcinolone acetonide for treatment of diabetic macular edema among Omani population
title Experience of intravitreal triamcinolone acetonide for treatment of diabetic macular edema among Omani population
title_full Experience of intravitreal triamcinolone acetonide for treatment of diabetic macular edema among Omani population
title_fullStr Experience of intravitreal triamcinolone acetonide for treatment of diabetic macular edema among Omani population
title_full_unstemmed Experience of intravitreal triamcinolone acetonide for treatment of diabetic macular edema among Omani population
title_short Experience of intravitreal triamcinolone acetonide for treatment of diabetic macular edema among Omani population
title_sort experience of intravitreal triamcinolone acetonide for treatment of diabetic macular edema among omani population
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657160/
https://www.ncbi.nlm.nih.gov/pubmed/29118493
http://dx.doi.org/10.4103/ojo.OJO_173_2016
work_keys_str_mv AT alhinaiahmed experienceofintravitrealtriamcinoloneacetonidefortreatmentofdiabeticmacularedemaamongomanipopulation
AT waliupenderkrishen experienceofintravitrealtriamcinoloneacetonidefortreatmentofdiabeticmacularedemaamongomanipopulation
AT rasooltayseerabdul experienceofintravitrealtriamcinoloneacetonidefortreatmentofdiabeticmacularedemaamongomanipopulation
AT rizvisyedg experienceofintravitrealtriamcinoloneacetonidefortreatmentofdiabeticmacularedemaamongomanipopulation